UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.

Nurix Therapeutics, a US-based oncology therapy developer based on research at University of California (UC), Berkeley and UC San Francisco, has filed to raise up to $100m in an initial public offering that would provide an exit for pharmaceutical producer Celgene. Founded in 2009 as Kura Therapeutics, Nurix is developing small molecule drugs intended to…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.